908 Devices Q2 EPS Estimate Increased by Leerink Partnrs

908 Devices Inc. (NASDAQ:MASS) – Stock analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for 908 Devices in a research note issued to investors on Tuesday, May 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.20) per share for the quarter, up from their prior estimate of ($0.21). The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices’ FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.54) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research note on Saturday, May 10th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.33.

908 Devices Price Performance

NASDAQ:MASS opened at $4.52 on Friday. The firm has a market cap of $161.54 million, a PE ratio of -2.55 and a beta of 0.26. 908 Devices has a 1-year low of $1.81 and a 1-year high of $7.27. The firm has a 50 day simple moving average of $4.58 and a 200-day simple moving average of $3.26.

908 Devices (NASDAQ:MASS) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. The business had revenue of $11.78 million during the quarter, compared to analysts’ expectations of $11.90 million.

Insider Transactions at 908 Devices

In related news, Director Mark Spoto acquired 10,000 shares of the business’s stock in a transaction on Wednesday, May 14th. The shares were bought at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the transaction, the director now directly owns 62,971 shares of the company’s stock, valued at $270,145.59. This trade represents a 18.88% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 27.70% of the company’s stock.

Institutional Investors Weigh In On 908 Devices

A number of large investors have recently modified their holdings of MASS. AQR Capital Management LLC purchased a new position in 908 Devices in the 1st quarter worth approximately $365,000. AWM Investment Company Inc. increased its holdings in 908 Devices by 210.6% in the first quarter. AWM Investment Company Inc. now owns 5,199,924 shares of the company’s stock valued at $23,296,000 after buying an additional 3,526,000 shares during the last quarter. First Light Asset Management LLC bought a new position in 908 Devices during the first quarter worth $7,621,000. PDT Partners LLC bought a new position in shares of 908 Devices in the 1st quarter worth about $186,000. Finally, American Century Companies Inc. raised its stake in 908 Devices by 10.8% during the first quarter. American Century Companies Inc. now owns 45,814 shares of the company’s stock worth $205,000 after acquiring an additional 4,471 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.